A Message from our Chief Scientific Officer
Francis Cuss, MB BChir, FRCP, Executive Vice President and Chief Scientific Officer
This is an important moment.
Having transformed Bristol-Myers Squibb into a benchmark BioPharma company, we now stand on the frontier of new possibilities regarding patient care. New medicines. New delivery systems. New hope.
The potential is real. The opportunities are endless.
Since late 2002, our R&D team has helped to bring to patients many new medicines to treat cancer, serious mental illness, HIV/AIDS, hepatitis B, rheumatoid arthritis, cardiovascular disease, organ transplant and diabetes. While our focus continues in many of these areas, we are also expanding our efforts to other diseases where the science beckons and the patient need is evident.
Our R&D strategy is to pursue significant areas of unmet medical need by leveraging our legacy in discovering and developing small molecules as well as our growing experience and expertise in biologic proteins.
As we look ahead to the future, our focus remains on building a pipeline of innovative therapies that expand the frontiers of biomedical research.
Most of all, our future depends on the people who work here. Each day, all around the world, we come to work committed to our Company mission: to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. This is our North Star.